Skip to main content

CCTG Connection


Published:
Category: Publications
Everolimus with or without bevacizumab in advanced pNET: CALGB 80701
 
This randomized phase II study demonstrated that the addition of bevacizumab to everolimus is associated with higher tumor response rates and improved progression-free survival in patients with advanced pancreatic neuroendocrine tumors. The higher rate of treatment-associated adverse events associated with the combination of bevacizumab and everolimus compared to everolimus alone precluded further investigation of this combination.
Read More
Published:
Category: Publications
Two new IND general review publications: Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022 and Meta-Analysis of the Test-Retest Repeatability of [18F]-Fluorodeoxyglucose Standardized Uptake Values: Implications for Assessment of Tumor Response Read More
Published:
Category: Trials

HN9 trial, a Randomized Phase II Study Of Cisplatin Plus Radiotherapy Versus Durvalumab Plus Radiotherapy Followed By Adjuvant Durvalumab Versus Durvalumab Plus Radiotherapy Followed By Adjuvant Tremelimumab And Durvalumab In Intermediate Risk HPV-Positive Locoregionally Advanced Oropharyngeal Squamous Cell Cancer (LA-OSCC), was closed to accrual with 121 of the planned 180 patients randomized.

Read More


Published:
Category: Group updates
NCI has provided a memo with additional information about Identity Proofing (IP) and Multi-Factor Authentication (MFA) for new user access to CTEP IAM accounts and CTSU websites. Links to the memos are available on the CTEP website. The memo for Canadian investigators is at the bottom of the page, under “Special Note for International Investigators.” Read More
Published:
Category: Publications
Low-Dose Metronomic Topotecan and Pazopanib (TOPAZ) in Children with Relapsed or Refractory Solid Tumors: A C17 Canadian Phase I Clinical Trial.
Manji A, Samson Y, Deyell RJ, Johnston DL, Lewis VA, Zorzi AP, Berman JN, Brodeur-Robb K, Morrison E, Kee L, Kumar S, Baruchel S, Whitlock JA, Morgenstern DA. Low-Dose Metronomic Topotecan and Pazopanib (TOPAZ) in Children with Relapsed or Refractory Solid Tumors: A C17 Canadian Phase I Clinical Trial.
Read More
Published:
Category: Publications
Dr Janet Dancey, Director CCTG
A generalized single-index linear threshold model for identifying treatment-sensitive subsets based on multiple covariates and longitudinal measurements| AND | Unified estimation for Cox regression model with nonmonotone missing at random covariates. Read More
Published:
Category: Trials
CCTG BLC5, a bladder cancer clinical trial is now open in Canada

CCTG BLC5 MAIN-CAV: Phase III Randomized Clinical Trial

The CCTG BLC5 MAIN-CAV international trial is now open in Canada testing the addition of a targeted anti-cancer drug to the usual immunotherapy treatment, in patients with metastatic urothelial cancer (mUC).This trial will test whether the addition of the anti-cancer drug, to the maintenance immunotherapy will or will not improve the patient’s overall survival.

Read More


Published:
Category: Group updates
CCTG Patient Representatives are in high demand. Recently some of our committee members have had the opportunity to share their experiences and expertise at stakeholder events both nationally and internationally. Read More